The role of topotecan in prolongation of platinum-free interval in patients with recurrent ovarian cancer

Nowadays disseminated ovarian cancer is a chronic disease, in the therapy of which one type of therapy completes the other; in case of recurrent ovarian cancer is important to change the regimens periodically. The choice of cytostatic drugs is quite wide, but in each case the tactic based on a combination of predictive factors, and also is important to take into account the toxicity after treatment. The article discusses the need and value of prolongation of platinum-free interval in relapsed ovarian cancer. In the preliminary assessment the Topotecan could be used as second-line and further-line treatment for recurrent ovarian cancer for platinum reinduction.